NasdaqGS:ALKSBiotechs
Alkermes Narcolepsy Trials Spark Interest In Growth And Valuation Upside
Alkermes (NasdaqGS:ALKS) has begun Phase 3 clinical trials for alixorexton, its orexin 2 receptor agonist for narcolepsy type 1 and type 2.
The late stage Brilliance Studies aim to evaluate alixorexton in patients with significant unmet treatment needs in sleep disorders.
This marks a new development in Alkermes' pipeline beyond prior focus areas highlighted in earlier coverage.
For Alkermes, known for its work in neuroscience and psychiatry, the Brilliance Studies add a new dimension to...